Drug maker Johnson & Johnson (NYSE: JNJ) is all set to embark on an extensive program to strengthen the product portfolio and
Categories
Health Care
Aurora Cannabis’ net loss widens in Q3
Like last quarter, Canadian-based cannabis producer Aurora Cannabis (NYSE: ACB) delayed its third-quarter earnings today. The company reported a loss of C$158
Aurinia Pharmaceuticals loss narrowed in Q1; AURORA trial on track
Aurinia Pharmaceuticals (NASDAQ:AUPH / TSX:AUP) narrowed its loss in the first quarter. Post the Q1 results, stock rose 2% in the after-market
Tilray Q1 loss widens, meets estimates
Tilray (TLRY) reported a wider loss in the first quarter of 2019 due to higher operating costs and expenses. The company is
Earnings: Agilent stock falls on Q2 earnings miss, weak guidance
Earnings of Agilent Technologies (Nasdaq: A), which manufactures instruments used in medical laboratories, increased in the second quarter but missed the market’s
Solid Biosciences tumbles 38% to hit historic low
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results that its
Earnings: Catabasis Q1 loss narrows on lower expenses, beats estimates
Catabasis Pharmaceuticals (Nasdaq: CATB) reported a narrower net loss for the first quarter of 2019. The improvement in the bottom line, which
InspireMD Q1 revenues plunge on third-party equipment failure
Israel-based medical device company InspireMD (NYSE: NSPR) reported a first-quarter loss of $3.82 per share, much wider than the loss of $2.50
CorMedix reports upbeat Q1 results; provides business update
Biopharmaceutical company CorMedix (CRMD) reported its first quarter 2019 results after the bell today. CorMedix recorded a net loss of $5.2 million
Catalyst Pharmaceuticals’ Q1 results beat estimates
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported first-quarter 2019 revenue and earnings that surpassed analysts’ expectations. Shares climbed around 4% in premarket hours on
Aurora Cannabis Q3 earnings: What’s in the cards?
Canadian-based cannabis producer Aurora Cannabis (NYSE: ACB) is slated to report its third-quarter results on May 14 after the bell followed by
Earnings preview: Agilent braces for an upbeat Q2 amid stable demand
Agilent Technologies (NYSE: A), which makes analytical instruments for laboratories, will be publishing its second-quarter financial results Tuesday after the market closes.
ESSA Pharma posts narrower loss in Q2
ESSA Pharma Inc. (EPIX) reported a narrower loss in the second quarter of 2019 helped by lower research and development expenses as
Earnings: Ocular Therapeutix Q1 loss widens on higher R&D expenses
Biopharmaceutical firm Ocular Therapeutix (Nasdaq: OCUL) reported a wider net loss for the first quarter - despite an increase in revenues -
Corbus Pharma’s Q1 results fall short of expectations
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) missed market expectations on revenue and earnings for the first quarter of 2019. The company reported
Cronos Group starts off fiscal 2019 with a profit in Q1
In the first quarter of 2019, Cronos Group (NASDAQ: CRON) more-than-doubled its revenues to C$6.5 million, primarily driven by the launch of the
Portola’s stock crashes 12% despite Q1 results beat
Shares of Portola Pharmaceuticals (NASDAQ: PTLA) plummeted 12.7% in morning trade on Wednesday despite the company achieving better-than-expected revenue and earnings for
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH
Cara Therapeutics Q1 loss widens but beats estimates
Cara Therapeutics Inc. (NASDAQ: CARA) reported a wider loss in the first quarter of 2019 due to higher costs and expenses. The bottom
Earnings preview: ‘Joint’ venture with Altria to help Cronos Group in Q1
Come Thursday and Cronos Group (NASDAQ: CRON) officially kicks off another season of cannabis stock earnings. The Toronto-based marijuana firm is scheduled
MannKind posts narrower-than-expected Q1 loss
MannKind Corporation (NASDAQ: MNKD) reported a narrower loss in the first quarter of 2019 helped by higher total revenues. The bottom line